Measurement of offline exhaled nitric oxide in a study of community exposure to air pollution. by Koenig, J Q et al.
Epidemiologic studies report consistent
adverse health effects of particulate matter
(PM) air pollution in population studies (U.S.
EPA 2001). However, describing the adverse
health effects of ﬁne PM exposure at the indi-
vidual subject level remains a high priority.
Studies designed to provide information con-
cerning these adverse effects include panel
studies with subjects followed for several days
or longer, clinical exposure studies, and toxi-
cologic studies, including controlled expo-
sures of human subjects. Panel studies are
usually designed to combine intensive per-
sonal, indoor and/or outdoor air monitoring
in conjunction with measures of specific
health outcomes. Recent panel studies have
concentrated on subjects believed to be sus-
ceptible to air pollution, such as those with
preexisting respiratory or cardiac disease. As a
consequence, the health end points commonly
measured are lung function, symptoms and
medication use, arterial oxygen saturation,
blood pressure, and heart rate variability.
Recent results from panel studies indicate sev-
eral adverse health effects associated with
exposure to PM with aerodynamic diameters
≤ 2.5 µm (PM2.5). In the United States,
decreased heart rate variability was associated
with indoor or outdoor PM2.5 in 26 elderly
subjects in Baltimore, Maryland (Liao et
al. 1999), in healthy subjects in Boston,
Massachusetts (Magari et al. 2002), in elderly
subjects with heart disease in Utah Valley,
Utah (Pope et al. 1999), and in elderly sub-
jects in Boston (Gold et al. 2000). Several
studies have reported associations between
exposure to fine particles and decrements in
lung function (Dockery et al. 1989; Koenig et
al. 1993) or increases in respiratory symptoms
(Yu et al. 2000). Two of these studies were
conducted with subjects with asthma in
Seattle, Washington. In a recent asthma panel
study in Alpine, California, Delfino et al.
(2002) found that symptom associations with
PM10, nitrogen dioxide, and ozone were
notably stronger in 12 asthmatics not taking
anti-inflammatory medications compared
with 10 subjects who did. Another study by
Delfino et al. (1998) which controlled for
severity by stratiﬁcation, found stronger asso-
ciations between asthma symptoms and both
PM10 and ozone among seven mild asthmatic
subjects not on anti-inflammatory medica-
tions compared with seven other mild asth-
matic subjects who were on anti-inﬂammatory
medications. These findings are instructive
regarding the spectrum of measurements of
asthma aggravation. However, few panel stud-
ies have investigated associations between
exposure to PM and lung inﬂammation.
Nitric oxide (NO) is a ubiquitous mole-
cule in the body and was named the molecule
of the year in 1992 based on its importance in
biologic systems (Culotta and Koshland 1992).
NO is generated from the oxidation of L-argi-
nine to L-citrulline by nitric oxide synthase
(NOS; Redington et al. 2001). It has been
shown that type II (inducible) NOS (iNOS) is
the form of the enzyme up-regulated during
lower airway inflammation (Gaston et al.
1994). iNOS is released by many cells in the
lung (macrophages, fibroblasts, neutrophils,
and epithelial cells (Lanz et al. 1999).
Expression of iNOS is up-regulated by inter-
feron γ, tumor necrosis factor α, and inter-
leukin 1β, all cytokines known to be active in
airway inﬂammation. These cytokines are sus-
pected to be the source of airway NO in sub-
jects with asthma (Yates 2001). Endogenous
NO is normally present in the pulmonary air-
ways and in exhaled breath, but it is elevated in
subjects with asthma (Redington et al. 2001).
In the lung, NO is involved in regulation of
vasodilation, in neurotransmission, and as an
agent of inflammation and cell-mediated
immunity (Yates 2001).
In the clinical setting, measurements of
exhaled nitric oxide (eNO) are suggested as a
sensitive measurement of airway inﬂammation
(Kharitonov and Barnes 2000; Slutsky et al.
1999) and as a diagnostic tool for identiﬁca-
tion of asthma (Jones et al. 2001). Jones et al.
(2001) report that eNO is as useful as induced
sputum or bronchial hyperresponsiveness test-
ing for assessing airway inflammation.
Subjects with asthma have elevated levels of
eNO compared with nonasthmatic subjects
(Jones et al. 2001; Silvestri et al. 2001; Yates
2001). NO plays a prominent role in oxida-
tive stress pathways. Several exogenous factors
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As part of a large panel study in Seattle, Washington, we measured levels of exhaled nitric oxide
(eNO) in children’s homes and ﬁxed-site particulate matter with aerodynamic diameters of 2.5 µm
or less (PM2.5) outside and inside the homes as well as personal PM2.5 during winter and spring ses-
sions of 2000–2001. Nineteen subjects 6–13 years of age participated; 9 of the 19 were on inhaled
corticosteroid (ICS) therapy. Exhaled breath measurements were collected ofﬂine into a Mylar bal-
loon for up to 10 consecutive days. Mean eNO values were 19.1 (SD ± 11.4) ppb in winter sessions
and 12.5 ± 6.6 ppb in spring sessions. Fixed-site PM2.5 mean concentrations were 10.1 ± 5.7 µg/m3
outside homes and 13.3 ± 1.4 inside homes; the personal PM2.5 mean was 13.4 ± 3.2 µg/m3. We
used a linear mixed-effects model with random intercept and an interaction term for medications
to test for within-subject–within-session associations between eNO and various PM2.5 values. We
found a 10 µg/m3 increase in PM2.5 from the outdoor, indoor, personal, and central-site measure-
ments that was associated with increases in eNO in all subjects at lag day zero. The effect was
4.3 ppb [95% conﬁdence interval (CI), 1.4–7.29] with the outdoor monitor, 4.2 ppb (95% CI,
1.02–7.4) for the indoor monitor, 4.5 ppb (95% CI, 1.02–7.9) with the personal monitor, and
3.8 ppb (95% CI, 1.2–6.4) for the central monitors. The interaction term for medication category
(ICS users vs. nonusers) was signiﬁcant in all analyses. These ﬁndings suggest that eNO can be
used as an assessment tool in epidemiologic studies of health effects of air pollution. Key words:
airway inﬂammation, asthma, children, exposure assessment, inhaled corticosteroids, nitric oxide,
panel study, personal exposure, PM2.5. Environ Health Perspect 111:1625–1629 (2003).
doi:10.1289/ehp.6160 available via http://dx.doi.org/ [Online 12 June 2003]
Environmental Medicine | Articleaffect the levels of eNO, such as alcohol con-
sumption, cigarette smoking (Bruce et al.
2002), sex (Tsang et al. 2001), circadian vari-
ation (Mattes et al. 2002), and asthma med-
ication (Yates 2001), indicating that careful
study design is required. Studies find that
eNO does not correlate highly with spiro-
metric measurements (Lanz et al. 1999;
Nightingale et al. 1999). A recent study
reported good reproducibility of eNO mea-
surements in both healthy and asthmatic
adults and children (Kharitonov et al. 2003).
These authors also tested the precision of the
measurements using one or two samples per
session. The difference in the worst case was
0.28 ± 5.8 ppb NO.
Several studies have reported the relation-
ship between inhaled corticosteroid (ICS)
therapy in subjects with asthma and eNO val-
ues. In one study of childhood respiratory dis-
eases including asthma, no difference in eNO
values by ICS use was observed (Narang et al.
2002). However, in a recent review several
studies were cited that reported higher eNO
values in ICS-naive subjects and reductions in
eNO when subjects are placed on ICS therapy
(Yates 2001). In a study of sequential changes
in eNO in children with asthma, Beck-Ripp
et al. (2002) observed that eNO values were
decreased when the children were on steroid
treatment. The concentrations of eNO were
elevated again after washout. One study
reported that montelukast added to ICS ther-
apy further reduced eNO levels in children
with asthma (Ghiro et al. 2002). Another
study came to the opposite conclusion and
reported a significant decrease in eNO with
ICS treatment but not with montelukast alone
(Kanniess et al. 2002).
As suggested above, eNO may be an
important indicator of asthma aggravation in
children with asthma. Mechanisms of adverse
effects of air pollutants such as ozone and PM
often involve oxidative stress and subsequent
tissue inflammation and injury. NO appears
to be involved in tissue injury (Moncada et al.
1991; Nathan 1992). Therefore, we decided
to explore the association between daily
changes in eNO and daily changes in ﬁne par-
ticle levels in a panel of children with asthma
in a planned exposure assessment and health
effects study in Seattle. Our hypotheses were
that we would observe an association between
eNO and PM2.5 and that the association
would be modiﬁed by the use of ICS therapy.
Materials and Methods
The research was part of an intensive exposure
assessment and health effects panel study of
susceptible subpopulations in Seattle from
1999 through 2002 (Liu et al. 2003). That
study was a 2-year comprehensive exposure
assessment study that examined PM exposures
in 108 individuals with and without chronic
obstructive respiratory disease, coronary artery
disease, and asthma. The health outcome mea-
surements collected were lung function, symp-
toms, medication use, and exhaled NO. In
this article, we report eNO results. eNO was
collected only in children with asthma.
Nineteen children, 6–13 years old, were
recruited from a local asthma and allergy clinic.
All had physician-diagnosed asthma and were
prescribed asthma medications daily or regu-
larly. Each child in the panel was asked to par-
ticipate for a 10-day monitoring session in the
winter of 2000–2001 and the spring of 2001.
Fourteen children participated in the eNO
study during the winter heating season, and 15
children participated during spring. Ten par-
ticipated in both seasons. Clinical character-
istics of the children are given in Table 1.
Approximately half of the children were pre-
scribed ICS therapy. Four subjects were on
other anti-inﬂammatory medications (three on
montelukast and one on cromolyn). Two sub-
jects were prescribed both ICS and mon-
telukast. The remainder of the subjects were
prescribed only inhaled albuterol as needed.
However, our analysis was designed to test the
hypothesis that ICS therapy would be associ-
ated with weaker associations between PM2.5
and eNO, and our medication interaction
term used only ICS medication. As mentioned
above, it is not clear whether montelukast
treatment affects airway eNO concentrations.
Exhaled breath measurements were col-
lected ofﬂine daily in the children’s homes into
an NO-inert and impermeable Mylar balloon
for up to 10 consecutive days. Jobsis et al.
(1999) found satisfactory agreement between
end expiratory plateau values of NO during
exhalation at 20% of vital capacity and NO val-
ues from collection by exhaling into a balloon.
Samples were collected in the afternoon
or early evening at the child’s residence.
Children were asked to forgo food intake for
1 hr before collection of exhaled breath.
Exhaled breath was collected before lung
function measurements, because deep inspira-
tions affect NO concentration (Deykin et al.
1998). The children were instructed to inhale
nearly to total lung capacity and exhale
through a Teﬂon straw with an inner diame-
ter of 3.5 mm and length of 35 cm until the
18-inch-diameter Mylar bag was filled
halfway (Jobsis et al. 1999). Reports show
that exhalation through a small-diameter
straw creates sufﬁcient pressure (at least 6 cm
H2O) to close the epiglottis and prevent cont-
amination of the airway NO sample by nasal
NO. Although we did not measure flow
directly, exhaled eNO values from individuals
in our laboratory using the straw technique
used in the field showed good comparison
with those collected from the same subject
using a manometer to verify flow rate (16.1
vs. 14 ppb in one test and 8.2 vs. 9.2 ppb in
another). Children were coached to maintain
an even flow rate. Deykin et al. (2002)
recently published data showing that ﬂow rate
variations do not affect eNO values signifi-
cantly within the range of 50–500 L/sec.
Because we did not measure NO levels in the
homes or scrub the inhaled air, we controlled
for ambient NO by adding outdoor central-
site ambient NO values for the time of eNO
collection to our regression model. Further,
we discarded data collected on days with high
outdoor NO (> 100 ppb).
NO was measured within 24 hr of collec-
tion using a chemiluminescent nitrogen oxide
(NOx) monitor (model 200A; API, San
Diego, CA). We tested the stability of NO in
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Table 1. Characteristics of pediatric subjects.
Subject no., Age Baseline Percent eNO
session (years) Sex FEV1(L)a predicted Average SD Medication
1 W,S 10 F 2.49 100 10.4 4.0 A
2 W,S 9 M 1.42 67 22.3 20.6 C, A, M
3 W,S 9 M 1.96 94 15.7 4.5 C, A, M
4 W 6 M 0.42 43 23.3 11.0 A
5 W,S 7 M NA NA 34.0 20.8 A, Cr
6 W 6 M 0.88 58 25.8 11.8 A
7 W,S 10 M 1.86 92 16.3 7.1 C, A
8 W,S 7 M 1.41 83 12.9 5.5 C, A
9 W 11 M 2.00 79 14.9 3.9 A
10 W,S 12 F 2.95 87 20.3 11.5 A, M
11 W,S 9 M 1.82 97 20.0 5.4 C, A
12 W 13 F 3.00 100 15.1 3.3 A
13 W,S 6 M 1.34 83 25.2 11.5 A, M
14 S 7 M 1.65 98 15.1 5.9 C, A
15 W,S 10 F 2.13 78 9.6 1.2 C
16 S 10 M 2.23 97 13.8 4.2 C
17 S 9 M 1.45 86 14.2 6.9 C
18 S 11 F 1.71 72 14.1 5.0 A
19 S 9 M 2.38 97 8.0 2.0 A, M
Abbreviations: A, albuterol; C, corticosteroid; Cr, cromolyn; M, montelukast; NA, not available; S, spring sessions; W, winter
sessions.
aPredicted FEV1. the Mylar bags by running comparisons of val-
ues immediately after collection and at 24 and
48 hr after collection. Over that time period,
NO values varied by less than 2 ppb (n = 8),
consistent with that found by Jobsis et al.
(2001). The NOx instrument was calibrated
by the Washington State Department of
Ecology (Olympia, WA) using a programma-
ble multigas calibrator (AMKO, Richmond
Hill, Ontario, Canada). During the eNO
analysis, the sample from the balloon was 500
cc/min (±10%) for 10 minutes until eNO val-
ues stabilized (6.5–78 ppb). The zero air was
scrubbed of NO with potassium perman-
ganate and charcoal. The sample from the bal-
loon was fed directly into the NOx analyzer
through a Nafion dryer (Perma Pure, Inc.,
Toms River, NJ), which equilibrated the sam-
ple with ambient relative humidity.
PM2.5 measurements were taken inside
and outside subjects’ residences using Harvard
impactors. Our research group evaluated the
performance of continuous PM monitors
(nephelometers) and Harvard impactors and
the Harvard personal environmental monitor
used in this panel study (Liu et al. 2002).
These integrated ﬁxed-site and personal mea-
surements were collected over 24 hr (1600 hr
to 1600 hr) for 10 consecutive session days.
PM2.5 concentrations also were monitored
continuously at three central sites (Beacon
Hill, Lake Forest Park, and Kent) with tapered
element oscillating microbalance (TEOM)
monitors, operated by the Puget Sound Clean
Air Agency. In addition, daily NO concentra-
tions were monitored continuously at the
Beacon Hill central site using a chemilumines-
cence monitor operated by the Washington
State Department of Ecology.
We used a linear mixed-effects model with
random intercept and interaction term for
medication to test for within-subject associa-
tions between eNO and various PM2.5 values.
The model included terms for within-subject,
within-session (10 day monitoring period)
effects; within-subject, between-session effects;
the confounding variable of temperature; and
NO measured at the Beacon Hill site. Our
primary interest was the within-subject,
within-session effects of PM2.5. Analyses were
conducted with all children from both winter
and spring sessions. STATA software was used
(Stata Corp., College Station, TX). The model
used was as follows:
where Xids is the PM2.5 reading for individual i
on day d during session s, X
–
is is the mean
PM2.5 reading for a subject during a session, X
–
i
is the mean PM2.5 reading for a subject during
all sessions, medi is an indicator for medica-
tion use (constant for each subject), Z ids is the
ambient NO reading for individual i on day d
during session s, Z
–
is is the mean ambient NO
reading for a subject during a session, and Z
–
i is
the mean ambient NO reading for a subject
during all sessions.
Results
During the winter, eight children had data for
all 10 days of each session, two had data for 9
days, and four had data for 8 days, for a total
of 130 person-days. None of the children had
fewer than 8 days of valid eNO values. During
the spring, three children had data for all 10
days, three for 9 days, ﬁve for 8 days, and two
for 7 days, for a total of 111 person-days.
Exposure assessment. The mean PM2.5 val-
ues from the monitors outside the residence
over the 10 days of study for the subjects
reported here was 13.3 ± 1.4 µg/m3; the mean
PM2.5 from the indoor monitors was 11.1 ±
4.9 µg/m3, and that from personal monitors
was 13.4 ± 3.2 µg/m3. The mean PM2.5 aver-
age value from the three central-site monitors
was 10.1 ± 5.7 µg/m3. The maximum PM2.5
values for outdoor, indoor, and personal mon-
itors were 40.4, 36.3, and 49.4 µg/m3, respec-
tively. During the study period, based on the
time–activity diary records, the children with
asthma spent an average of 66% of their time
indoors at home and 21% indoors away from
home (primarily at school). They spent 4.4%
of their time in transit and 6.4% outdoors.
The interquartile range of PM2.5 for the moni-
tors outside the homes was 9.8 µg/m3 during
the winter sessions and 5.3 µg/m3 during the
spring sessions.
eNO assessment. Inhaled NO may affect
concentrations of airway NO. Therefore, we
included central-site NO values (supplied by
the Washington State Department of Ecology)
in our linear mixed-effects model. Hourly NO
values from a central-site monitor were avail-
able for each day of eNO collection in this
study. Central-site NO values were correlated
with the daily outdoor PM2.5 (r = 0.50) and
with daily eNO values (r = 0.43). However,
the correlation between central-site NO and
daily outdoor PM2.5 was reduced substantially
for NO values less than 100 ppb (r = 0.04).
The average eNO concentration for all
children over 10 days was 19.9 ± 12.4 ppb
during the winter sessions (10 day monitoring
periods) and 12.7 ± 6.7 ppb during the spring
sessions. We found associations between eNO
levels and PM2.5 levels in the children studied
during combined winter and spring monitor-
ing sessions for all four exposure metrics (out-
side the home, inside the home, personal, and
central-site average). In all cases, there were
significant interactions between PM2.5 con-
centrations and medication use category (ICS
users or nonusers). Summaries of these data
are given in Table 2. Results are expressed as a
10 µg/m3 increase in PM2.5 concentration rel-
ative to session average for that subject and
for zero day lag. The association with PM2.5
values from the monitor outside the home for
ICS nonusers was a 4.3 ppb [95% conﬁdence
interval (CI), 1.4–7.2] increase in eNO. The
other associations between PM2.5 and eNO
were with indoor monitor (4.2 ppb), personal
monitor (4.5 ppb), and the average central-
site monitor value (3.8 ppb; CIs are given in
Table 2). No associations were seen in the
children on ICS therapy. Figure 1 shows indi-
vidual slopes plotting eNO values against
PM2.5 values from the monitor outside the
home. Slopes are identified by subject num-
ber (see Table 1 for subject characteristics).
Discussion
In this study we found a consistent relation-
ship between daily eNO values in children
with asthma and daily PM2.5 measured at ﬁxed
sites and on subjects. As hypothesized, we
found that the use of ICS therapy modified
the association between eNO and PM2.5.
Including ambient NO values for the hour of
the home visit from a central site in our model
and discarding high NO days (> 100 ppb)
attenuated the magnitude but did not alter the
association between PM2.5 and eNO in all
analyses. Same-day outdoor, indoor, personal,
and central PM2.5 levels were associated with
eNO in either analysis.
At the time we collected these data, we
were not using a system that scrubbed ambient
NO. There is a possibility that elevated levels
of inspired NO affected the levels of eNO. The
levels of inspired NO are due to both indoor-
generated NO as well as NO that has infil-
trated from outdoors. We do not think that
indoor-generated NO affected the association
found here, for three reasons: a) There is no
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Table 2. Association between eNO (ppb) and PM2.5 (µg/m3), winter and spring sessions, controlling for
ambient NO and removing high outdoor NO days (> 100 ppb; n = 19).
Change in eNO (95% CI) per 10 µg/m3 increase in PM 2.5
Monitor ICS nonuser (n = 10) ICS user (n = 9)
Personal 4.48 (1.02–7.93) –0.09 (–2.39 to 2.21)
Outdoor 4.28 (1.38–7.17) 0.74 (–2.28 to 3.76)
Indoor 4.21 (1.02–7.41) –1.11 (–5.08 to 2.87)
Central site 3.82 (1.22–6.43) 1.28 (–1.23 to 3.79)obvious reason why indoor NO would vary
with subject’s medication use; b) although ﬁve
of the homes had gas cooking stoves, which
could increase indoor NO levels, there was no
correlation between eNO values and the pres-
ence of a gas stove; c) because outdoor NO can
potentially affect inhaled indoor NO and thus
eNO, we eliminated those days with outdoor
NO > 100 ppb in our analysis, and the signiﬁ-
cance of the association was unchanged
(p < 0.004). At the present time, the relation-
ships between indoor, outdoor, and personal
air pollution and health outcomes are being
studied vigorously by several investigators. The
role of confounding variables is one concern.
We present our data as a contribution to this
ongoing literature.
The use of exhaled NO as a novel bio-
marker of adverse respiratory health effects was
suggested by van Amsterdam et al. (2000),
who had previously found an association
between exhaled NO values and high levels of
outdoor air pollution in the Netherlands in
healthy, nonsmoking subjects (van Amsterdam
et al. 1999). Ambient carbon monoxide and
NO were highly correlated with the collected
eNO. More recently, eNO levels were associ-
ated with exposure to PM10, black smoke,
nitrogen dioxide, and ambient NO in a
panel study of children in the Netherlands
(Steerenberg et al. 2001). Adamkiewicz et al.
(2002) presented preliminary data showing an
association between measures of air pollution
and eNO values in a panel of elderly nonsmok-
ing subjects in Steubenville, Ohio. Their analy-
sis found a 1.46 (95% CI, 0.29–2.63) ppb
increase in eNO for a mean interquartile range
increase in PM2.5. The effect found in the pre-
sent study was stronger, which is not surprising
because children with asthma are known to be
at risk for airway inﬂammation.
Exhaled NO has been measured in con-
trolled studies of air pollution exposures to 0.2
ppm ozone in healthy subjects; no signiﬁcant
changes in exhaled NO were found either at
6 or 24 hr after exposure (Olin et al. 2001).
Newson et al. (2000) also found that eNO
values did not change after exposure of 
subjects with mild atopic disease to 0.2 ppm
ozone for 2 hr. A similar study was reported by
Nightingale et al. (1999), who found no change
in eNO after exposure of subjects with asthma
to 0.2 ppm ozone for 2 hr, even though forced
expiratory volume in 1 sec (FEV1) decreased
9%. On the other hand, exposure to active cig-
arette smoke is associated with an increase in
NO metabolites in breath condensate in cur-
rent smokers (Balint et al. 2001).
Because many epidemiologic studies rely
on central-site monitors for evaluations of
health outcomes, there is concern about
whether central-site data are representative of
residences. One of the goals of our large
intensive indoor/outdoor and personal PM
monitoring study was to evaluate the relation-
ship between central-site and residential PM
monitors (Liu et al. 2003). Our data indicate
that eNO effects estimated from central ﬁxed-
site monitors are similar to effects estimated
from monitors outside and inside homes and
personal monitors.
The mean eNO values in our study (19
and 12 ppb, winter and spring sessions,
respectively) agree with values seen in subjects
with asthma in several other studies. Beck-
Ripp et al. (2002) report an average value of
14.9 ± 1.9 ppb in a group of 34 children with
asthma not treated with corticosteroids. The
average decreased to 7.6 ± 0.8 ppb after
4 weeks on ICS therapy. Another study of
eNO found an average 15.9 ± 14.9 ppb in
atopic children versus 7.6 ± 1.6 ppb in
nonatopic children (Silvestri et al. 2001).
However, there are reports of much higher
eNO values in similar populations. For
instance, Lanz et al. (1999) reported an aver-
age of 48 ± 8 ppb in a group of children with
asthma before ICS treatment. These children
were experiencing acute exacerbations of
asthma. Because the field of eNO measure-
ments is emerging, standard operating proto-
cols for breath collection and analysis are still
evolving, and normative population values of
lung NO in subjects with or without asthma
are not known with certainty.
Outdoor sources of PM2.5 in Seattle are
wood smoke from residential wood stoves,
diesel exhaust particles from trucks and buses,
and automotive traffic. Seattle is one of the
most traffic-congested cities in the United
States. One source-apportionment study eval-
uated speciated data from the Beacon Hill site
in Seattle using positive matrix factorization
(Maykut et al. Unpublished data). The
authors estimated the major sources contribut-
ing to PM2.5 in Seattle to be vegetative burn-
ing (35%), mobile sources (22%), and sulfate
(20%), with road dust, nitrate, and marine
aerosol making up the balance. The present
study found consistent associations between
PM2.5 and eNO from children studied during
both winter and spring; there was no signiﬁcant
Environmental Medicine | Koenig et al.
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Figure 1. Relationships between eNO and PM2.5 from the monitor outside the home for each of the 19 children
in the study (1–19). Ten of the children participated in both the winter (W) and spring (S) sessions. Table 1
gives characteristics of the individual children.
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● ● ● ● ● ● ● ● ● ● ●season effect. However, PM2.5 values were
considerably higher during winter (interquar-
tile range = 9.8 µg/m3 in winter vs. 5.3 µg/m3
in spring). Winter is the time of year when
ﬁne particles from wood stoves predominate.
Interestingly, personal exposure as well as
outdoor exposure to PM was associated with
eNO. Very few data address health effects in
studies reporting personal exposure values.
Personal monitor values are affected by both
outdoor and indoor sources. The children in
this study spent approximately 93% of their
time indoors. The associations between eNO
values and personal PM2.5 are biologically
plausible. A large number of studies document
indoor sources of environmental agents that can
aggravate asthma (e.g., Carter et al. 2001;
Eggleston and Bush 2000; Shapiro et al. 1999).
These sources include cat dander, environmen-
tal tobacco smoke, molds, and dust mites.
Homes with smokers were excluded from our
panel study, but the other indoor asthma trig-
gers are ubiquitous. Along with these asthma
triggers, personal exposures include PM from
many personal activities such as cooking or vac-
uuming, as well as vehicle exhaust because of
close proximity to these sources.
We conclude that these data suggest
ambient PM2.5 exposure in Seattle is associ-
ated with an increase in eNO in children
with asthma. Because eNO is a marker of air-
way inflammation, and PM has been shown
to cause inﬂammation in animal studies, our
result is biologically plausible. This finding
also agrees with previous asthma research in
Seattle that showed associations between
PM2.5 and lung function decrements in chil-
dren (Koenig et al. 1993), visits to emergency
departments for asthma (Norris et al. 1999),
hospitalizations for asthma (Sheppard et al.
1999), and increases in asthma symptoms in
children (Yu et al. 2000). Finally, we suggest
that collection of eNO in a ﬁeld-panel study
can be used to assess the effects of ambient
air pollution. These findings confirm that
eNO may be an effective, noninvasive tool
for epidemiologic studies of health effects of
air pollution.
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